Sebastian Thams

Sebastian Thams

Resident in Neurology and Researcher

Dr. Sebastian Thams is a resident in neurology at Karolinska university hospital with focus on ALS and neuromuscular disorders. He has 10+ years of experience in basic and translational research, including a 4 year postdoc period at Columbia University motor neuron center, where he worked on small molecule screening and development of new drug candidates in ALS. Dr. Thams’ current research focuses on disease mechanisms and drug discovery in iPS-derived motor neurons from ALS patients with familial disease.

Connect
Connect trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial

This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.

Read more
Active
Phase iii

VALOR study

Industry trial

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more